Form 4 for FULC Fulcrum Therapeutics, Inc.
Accepted 2023-01-13 00:00:00 ET · period of report 2023-01-13 · accession 0000899243-23-001803 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-01-13 | 2023-01-13 | FULC | Gould Robert J | CEO, Interim Pres, Dir | S - Sale | $15.00 | -6,766 | 499.9K | -1% | -$101.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-01-13 | S | D | 6,766 | $15.00 | 499,864 | D | — | — |